Phase 3 STRIVE Study Of VX-770 Showed Durable Improvements In Lung Function And Other Measures Of Disease Among People With A Specific Type Of CF
Links shared publicly online about this topic.
- 229total visits
Phase 3 STRIVE Study Of VX-770 Showed Durable Improvements In Lung Function And Other Measures Of Disease Among People With A Specific Type Of CF
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defec
View full resource at medicalnewstoday.com
Tags: Lung, Disease and Condition, Pharma, disease, Medical
Most Recently Shared on June 10, 2011 at 5:05 pm By:
Phase 3 STRIVE Study Of VX-770 Showed Durable Improvements In Lung Function And Other Measures Of Disease Among People... http://mnt.to/3X4C
Advertisement
